Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative

Erika Murce, Stephen Ahenkorah, S. Beekman, Lilian van den Brink, Simone Dalm, Frederik Cleeren, Yann Seimbille

    Research outputpeer-review


    Prostate specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer, as illustrated by PSMA-617 (PluvictoTM). Development of optimized PSMA-targeting probes has focused on theranostic (therapy + diagnosis) approaches, where the same precursor can be radiolabeled with similar or identical nuclides, allowing for personalised dosimetry estimation and radionuclide therapy of patients. 3p-C-NETA is a promising chelator which has been shown to efficiently label therapeutic (177Lu, 161Tb, 213Bi) and diagnostic (68Ga, Al18F) nuclides1. In this study, we attached this chelator to a PSMA-targeting derivative and compared it to a derivative containing a DOTA-GA chelator and to the gold standard PSMA-617.
    Original languageEnglish
    Title of host publicationEuropean Journal of Nuclear Medicine and Molecular Imaging
    Subtitle of host publicationAnnual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain
    PublisherSpringer Link
    Number of pages1
    StatePublished - 22 Sep 2022

    Publication series

    NameEuropean Journal of Nuclear Medicine and Molecular Imaging
    PublisherSpringer Link
    ISSN (Print)1619-7070
    ISSN (Electronic)1619-7089

    Cite this